✕
Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
 简体中文
(Simplified Chinese) 繁體中文
(Traditional Chinese)
OPHTHALMOLOGY
There is a brighter future through fluorescent technology.
MediBeacon Ocular Angiography Program

CLINICAL PROGRAM
MediBeacon is poised to begin first in-human clinical studies to establish the feasibility of using Lumitrace® to visualize the vasculature of the eye in ocular angiography systems.*

FUNDING FROM THE NATIONAL EYE INSTITUTE
A Small Business Innovation Research (SBIR) grant supported by the National Eye Institute (NEI) of the National Institutes of Health (NIH) under Award Number R43EY027207 was awarded to MediBeacon in support of research into the use of a MediBeacon fluorescent tracer agent to visualize vasculature in the eye.

Use of fluorescent agent-based ocular angiography can show retinal circulation details that are not seen in imaging technologies that do not employ a tracer agent.
– Retina Today, J. Chhablani et al., Fluorescein Angiography and Optical Coherence Tomography correlation in various retinal diseases, January/February 2014
Diagnosing and monitoring vasculature leakage in the eye is a key factor in diagnosing and monitoring various disease states including the following.
Diabetic Retinopathy
Diabetic Retinopathy is the most common cause of vision loss among diabetics and a leading cause of blindness in working-age adults.
- National Eye Institute, nei.nih.gov/health/diabetic/retinopathy
Macular Degeneration
Macular Degeneration is the leading cause of vision loss, affecting more than 10 million Americans.
- American Macular Degeneration Foundation, macular.org
Retinal Vasculitis
Retinal Vasculitis is the inflammation of retina vessels. Detection and characterization may help in diagnosis and management of certain disorders including systemic autoimmune disorders, some infectious diseases, and certain ocular disorders.
- La Revue de Médecine Interne, P. Gascon et al., Retinal vasculitis and systemic diseases, September 2018

United States
MediBeacon Inc.
425 N. New Ballas Road
Suite 100
St. Louis, MO 63141
P: (314) 269-5808

Germany
MediBeacon GmbH
Cubex41
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
P: +49 (0)621-150283-15

Greater China
(Exclusive Commercial Partner)
Huadong Medicine Co., Ltd
Telephone: 4008-269-985
+86-(0)571-89908581
Zip: 310011
Address: No.866. Moganshan Road, Hangzhou, Zhejiang Province, China
Email: info@eastchinapharm.com

Science How it Works R&D Platform Product Pipeline Patent Estate Preclinical Clinical Focus Areas Nephrology Gastroenterology Ophthalmology Surgery In Discovery
Publications MediBeacon Publications Preclinical Publications Industry Literature Company History People By the Numbers Quality Commitment News/Media Contact Get Updates Investors General Questions

*MediBeacon products are in various stages of clinical development and are not yet approved for human use.

**The Transdermal GFR Measurement System (TGFR) is intended to measure Glomerular Filtration Rate (GFR) in patients with impaired or normal renal function. References on this website to measured kidney function and measured renal function refer to the measured GFR.

Terms and Conditions | Privacy Policy | © 2021 MediBeacon All Rights Reserved.

COOKIE CONSENT: We use cookies and similar technologies to recognize your repeat visits and preferences, as well as to analyze traffic, among other things. To learn more about cookies, view our Privacy Policy. By clicking “I Accept” on this banner, or using our site, you consent to the use of cookies unless you have disabled them.